Data Supplement 1: Association of Pulmonary Embolism Severity Index (PESI) scores with outcomes. Estimates of main treatment effects by time period using logistic regression models.

Time Window	Outcome Variable	Effect	Odds Ratio	95% CI
Up to 7 days after randomization	Recurrent VTE	PESI 1 vs. 0	0.808	0.248–2.343
	Recurrent VTE	PESI ≥2 vs. 0	4.350	1.547–11.738
	Recurrent VTE	Rivaroxaban vs enoxaparin/VKA	1.077	0.453–2.594
	PE-related death	PESI 1 vs. 0	1.519	0.060–38.416
	PE-related death	PESI ≥2 vs. 0	17.573	2.242–355.792
	PE-related death	Rivaroxaban vs enoxaparin/VKA	0.235	0.012–1.594
	All deaths	PESI 1 vs. 0	2.964	0.284–63.794
	All deaths	PESI ≥2 vs. 0	40.105	7.108–751.068
	All deaths	Rivaroxaban vs enoxaparin/VKA	0.617	0.157–2.176
	Major bleeding	PESI 1 vs. 0	1.064	0.314–3.340
	Major bleeding	PESI ≥2 vs. 0	4.102	1.209–12.916
	Major bleeding	Rivaroxaban vs enoxaparin/VKA	0.531	0.183–1.401
Up to 14 days after randomization	Recurrent VTE	PESI 1 vs. 0	1.255	0.569–2.726
	Recurrent VTE	PESI ≥2 vs. 0	3.626	1.502–8.318
	Recurrent VTE	Rivaroxaban vs enoxaparin/VKA	0.922	0.469–1.801
	PE-related death	PESI 1 vs. 0	1.502	0.180–12.533
	PE-related death	PESI ≥2 vs. 0	8.658	1.430–65.926
	PE-related death	Rivaroxaban vs enoxaparin/VKA	0.382	0.055–1.778
	All deaths	PESI 1 vs. 0	2.967	0.578–21.415
	All deaths	PESI ≥2 vs. 0	25.893	6.641–170.270
	All deaths	Rivaroxaban vs enoxaparin/VKA	0.621	0.207–1.733
	Major bleeding	PESI 1 vs. 0	1.120	0.456–2.654
	Major bleeding	PESI ≥2 vs. 0	2.880	0.998–7.464
	Major bleeding	Rivaroxaban vs enoxaparin/VKA	0.489	0.209–1.064
Up to 30 days after randomization	Recurrent VTE	PESI 1 vs. 0	1.393	0.723–2.671
	Recurrent VTE	PESI ≥2 vs. 0	3.588	1.683–7.358
	Recurrent VTE	Rivaroxaban vs enoxaparin/VKA	0.861	0.486–1.515
	PE-related death	PESI 1 vs. 0	2.991	0.583–21.593
	PE-related death	PESI ≥2 vs. 0	8.596	1.420–65.430
	PE-related death	Rivaroxaban vs enoxaparin/VKA	0.475	0.100–1.805
	All deaths	PESI 1 vs. 0	10.287	2.869–65.558

Time Window	Outcome Variable	Effect	Odds Ratio	95% CI
Up to 90 days after randomization	All deaths	PESI ≥2 vs. 0	48.888	13.949–308.965
	All deaths	Rivaroxaban vs enoxaparin/VKA	0.988	0.493–1.987
	Major bleeding	PESI 1 vs. 0	1.200	0.549–2.568
	Major bleeding	PESI ≥2 vs. 0	3.495	1.458–7.911
	Major bleeding	Rivaroxaban vs enoxaparin/VKA	0.427	0.201–0.849
	Recurrent VTE	PESI 1 vs. 0	1.107	0.650–1.863
	Recurrent VTE	PESI ≥2 vs. 0	2.750	1.464–4.960
	Recurrent VTE	Rivaroxaban vs enoxaparin/VKA	0.983	0.619–1.560
	PE-related death	PESI 1 vs. 0	1.454	0.343–6.159
	PE-related death	PESI ≥2 vs. 0	6.965	1.835–28.237
	PE-related death	Rivaroxaban vs enoxaparin/VKA	1.124	0.372–3.502
Up to end of intended treatment period	All deaths	PESI 1 vs. 0	3.527	1.731–7.745
	All deaths	PESI ≥2 vs. 0	16.406	8.174–35.736
	All deaths	Rivaroxaban vs enoxaparin/VKA	1.076	0.648–1.796
	Major bleeding	PESI 1 vs. 0	1.573	0.847–2.930
	Major bleeding	PESI ≥2 vs. 0	3.191	1.466–6.594
	Major bleeding	Rivaroxaban vs enoxaparin/VKA	0.512	0.282–0.898
	Recurrent VTE	PESI 1 vs. 0	1.109	0.693–1.760
	Recurrent VTE	PESI ≥2 vs. 0	2.702	1.541–4.586
	Recurrent VTE	Rivaroxaban vs enoxaparin/VKA	1.121	0.744–1.694
	PE-related death	PESI 1 vs. 0	1.441	0.400–5.189
	PE-related death	PESI ≥2 vs. 0	8.877	2.947–29.500
	PE-related death	Rivaroxaban vs enoxaparin/VKA	1.511	0.592–4.122
Up to last dose of study medication + 2 days	All deaths	PESI 1 vs. 0	4.450	2.533–8.277
	All deaths	PESI ≥2 vs. 0	19.595	11.141–36.501
	All deaths	Rivaroxaban vs enoxaparin/VKA	1.097	0.743–1.624
	Major bleeding	PESI 1 vs. 0	1.900	1.144–3.187
	Major bleeding	PESI ≥2 vs. 0	3.706	1.965–6.803
	Major bleeding	Rivaroxaban vs enoxaparin/VKA	0.478	0.293–0.761

CI = confidence interval; PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; VKA = vitamin K antagonist; VTE = venous thromboembolism.